CN108135883B - 含有芳基烷基胺化合物的药物组合物 - Google Patents

含有芳基烷基胺化合物的药物组合物 Download PDF

Info

Publication number
CN108135883B
CN108135883B CN201680058580.7A CN201680058580A CN108135883B CN 108135883 B CN108135883 B CN 108135883B CN 201680058580 A CN201680058580 A CN 201680058580A CN 108135883 B CN108135883 B CN 108135883B
Authority
CN
China
Prior art keywords
weight
parts
pharmaceutical composition
cellulose
starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680058580.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN108135883A (zh
Inventor
谷村信尔
吉井宏子
岩田见二
井泽直人
太田元洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58538545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108135883(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Priority claimed from PCT/JP2016/080013 external-priority patent/WO2017061621A1/ja
Publication of CN108135883A publication Critical patent/CN108135883A/zh
Application granted granted Critical
Publication of CN108135883B publication Critical patent/CN108135883B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680058580.7A 2015-10-07 2016-10-07 含有芳基烷基胺化合物的药物组合物 Active CN108135883B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2015-199694 2015-10-07
JP2015199694 2015-10-07
JP2016-197725 2016-10-06
JP2016197725A JP6168673B2 (ja) 2015-10-07 2016-10-06 アリールアルキルアミン化合物含有医薬組成物
PCT/JP2016/080013 WO2017061621A1 (ja) 2015-10-07 2016-10-07 アリールアルキルアミン化合物含有医薬組成物

Publications (2)

Publication Number Publication Date
CN108135883A CN108135883A (zh) 2018-06-08
CN108135883B true CN108135883B (zh) 2021-09-14

Family

ID=58538545

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680058580.7A Active CN108135883B (zh) 2015-10-07 2016-10-07 含有芳基烷基胺化合物的药物组合物

Country Status (6)

Country Link
US (1) US10350194B2 (enExample)
EP (1) EP3360551A4 (enExample)
JP (2) JP6168673B2 (enExample)
KR (1) KR102000897B1 (enExample)
CN (1) CN108135883B (enExample)
TW (2) TWI808349B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100800708B1 (ko) * 2001-09-27 2008-02-01 삼성전자주식회사 키 텔레폰 시스템의 포트 상태 진단 방법
CN108379588B (zh) * 2018-03-05 2024-07-02 合肥合源药业有限公司 托吡酯组合物
WO2020111089A1 (ja) * 2018-11-27 2020-06-04 協和キリン株式会社 医薬組成物
EP4029867A1 (en) * 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate
CN115006363A (zh) * 2022-06-23 2022-09-06 上海信谊万象药业股份有限公司 一种牡蛎碳酸钙咀嚼片及其制备方法
JP2024023047A (ja) * 2022-08-08 2024-02-21 日医工株式会社 ビルダグリプチン含有医薬品
CN115381094B (zh) * 2022-08-18 2023-10-24 河南中大恒源生物科技股份有限公司 一种低臭味水溶性叶绿素铜及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115975A1 (ja) * 2004-05-28 2005-12-08 Tanabe Seiyaku Co., Ltd. アリールアルキルアミン化合物及びその製法
WO2015034031A1 (ja) * 2013-09-05 2015-03-12 田辺三菱製薬株式会社 新規な結晶性アリールアルキルアミン化合物およびその製造方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4880457A (enExample) 1972-01-31 1973-10-27
JPS5547615A (en) * 1978-09-29 1980-04-04 Taiyo Yakuhin Kogyo Kk Stable solid drug of nifedipine
JP2914690B2 (ja) * 1989-12-13 1999-07-05 グレラン製薬株式会社 安定なビタミンｄ▲下３▼類含有製剤
JP2001233766A (ja) * 2000-11-15 2001-08-28 Ohara Yakuhin Kogyo Kk プラバスタチンナトリウムの錠剤
JP2003104887A (ja) * 2001-09-28 2003-04-09 Maruko Seiyaku Kk 光に安定なアラニジピン含有組成物
ES2299710T3 (es) 2002-08-02 2008-06-01 Ratiopharm Gmbh Preparacion farmaceutica que contiene un compuesto de bencimidazol mezclado con celulosa microcristalina y un metodo para su preparacion.
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
JP4018664B2 (ja) * 2003-04-30 2007-12-05 第一三共株式会社 安定化固形製剤
GB0316206D0 (en) 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
TWI346114B (en) 2003-09-29 2011-08-01 Method for stabilization of diarylvinylene compounds
JP2005154431A (ja) * 2003-11-07 2005-06-16 Takeda Chem Ind Ltd 固形製剤
WO2005044223A1 (en) 2003-11-07 2005-05-19 Takeda Pharmaceutical Company Limited Chewable tablet
JP4783573B2 (ja) * 2004-02-20 2011-09-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ワルファリンカリウム含有医薬組成物とその製造方法
MXPA06012566A (es) * 2004-04-30 2007-05-09 Bkg Pharma Aps Tratamiento de enfermedades infecciosas.
JP2007032370A (ja) * 2005-07-25 2007-02-08 Aisin Seiki Co Ltd 電動ポンプ
EP1828098A1 (en) * 2005-11-22 2007-09-05 Teva Pharmaceutical Industries Ltd Crystal forms of cinacalcet hci and processes for their preparation
SI1880718T1 (sl) * 2006-07-10 2011-11-30 Pfleger R Chem Fab Farmacevtski pripravki za oralno dajanje z nadzorovanim sproščanjem zdravila v majhne intestinke kolone in postopek njihove priprave
GB0724478D0 (en) 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
WO2010067204A1 (en) * 2008-12-08 2010-06-17 Actavis Group Ptc Ehf Highly pure cinacalcet or a pharmaceutically acceptable salt thereof
WO2010087462A1 (ja) * 2009-01-29 2010-08-05 大日本住友製薬株式会社 内核を有する口腔内崩壊錠
WO2011082980A2 (de) 2009-12-16 2011-07-14 Basf Se Filmüberzugsmittel basierend auf polyvinylalkohol-polyether-pfropfcopolymeren- polyvinylalkohol-kombinationen mit verbesserter feuchtigkeitsbarrierewirkung
JP6133009B2 (ja) 2010-08-11 2017-05-24 協和発酵キリン株式会社 トピラマート顆粒

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115975A1 (ja) * 2004-05-28 2005-12-08 Tanabe Seiyaku Co., Ltd. アリールアルキルアミン化合物及びその製法
WO2015034031A1 (ja) * 2013-09-05 2015-03-12 田辺三菱製薬株式会社 新規な結晶性アリールアルキルアミン化合物およびその製造方法

Also Published As

Publication number Publication date
EP3360551A4 (en) 2019-07-31
JP6168673B2 (ja) 2017-07-26
TWI808349B (zh) 2023-07-11
TW202110435A (zh) 2021-03-16
US20180296526A1 (en) 2018-10-18
EP3360551A1 (en) 2018-08-15
US10350194B2 (en) 2019-07-16
JP2017071605A (ja) 2017-04-13
TWI708603B (zh) 2020-11-01
TW201717937A (zh) 2017-06-01
CN108135883A (zh) 2018-06-08
KR102000897B1 (ko) 2019-07-16
JP2017071599A (ja) 2017-04-13
KR20180054870A (ko) 2018-05-24

Similar Documents

Publication Publication Date Title
US11007152B2 (en) Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
ES2522297T3 (es) Una forma farmacéutica que contiene dos principios activos farmacéuticos en diferentes formas físicas
JP6168673B2 (ja) アリールアルキルアミン化合物含有医薬組成物
EP2815752B1 (en) Oral pharmaceutical composition
US10583087B2 (en) Pharmaceutical composition for oral administration
CN116490178A (zh) Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途
ES2901598T3 (es) Comprimido recubierto con película que tiene una alta estabilidad química del ingrediente activo
JP2017071605A5 (enExample)
EP4240331B1 (en) Solid formulation
JP5490347B2 (ja) 経口投与用製剤
CA2869882C (en) Capsule formulation
KR102488488B1 (ko) 아릴알킬아민 화합물 함유 의약 조성물
JP2013216701A (ja) 経口投与用製剤
CN113164436A (zh) 药物组合物
US9775832B2 (en) Pharmaceutical composition for oral administration
JP2022151564A (ja) 薬効成分としてビルダグリプチンおよびメトホルミンを含む錠剤
HK40058353A (en) Pharmaceutical composition
JP2024110379A (ja) 安定なマシテンタン含有医薬組成物
WO2014002851A1 (ja) 固形医薬錠剤およびその製造方法
WO2014007065A1 (ja) 固形医薬錠剤およびその製造方法
HK40047994B (en) Pharmaceutical composition containing poorly soluble basic medicine
JP2012012411A (ja) 経口投与用製剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Tokyo, Japan

Applicant after: Union Kirin Co., Ltd.

Address before: Tokyo, Japan

Applicant before: Kyowa Hakko Kirin Co., Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant